Telix Expands Board With Appointments Of Maria Rivas And Bill Jellison To Strengthen Governance And Strategy

Telix Pharmaceuticals Limited has announced the appointment of two new Non-Executive Directors, Maria Rivas and William Jellison, effective May 11, 2026. These appointments are part of the company’s broader board expansion and succession planning strategy to strengthen governance and leadership.

Dr. Rivas brings more than 25 years of experience in clinical development, commercialization, and governance across the pharmaceutical and medical device sectors. She has previously served as Chief Medical Officer at Pfizer, Inc. and currently sits on the board of The Cooper Companies, Inc.. Her career includes leadership in global healthcare operations and the successful launch of multiple major therapies across oncology, rare diseases, and neuroscience.

Telix Interim Chair, Dr. Mark Nelson, commented on the appointments, “We are delighted to welcome Maria and Bill, highly accomplished Non-Executive Directors whose collective experience in U.S. public company governance, financial oversight and clinical leadership will significantly enhance the Board’s capability. Along with the recent addition of David Gill, these appointments are well aligned with Telix’s evolution as a dual-listed, global, commercial stage biopharmaceutical company.”

Mr. Jellison contributes over three decades of experience in corporate finance and public company governance. He currently serves on the boards of several organizations, including Medtronic plc and Anika Therapeutics, Inc.. Previously, he served as Chief Financial Officer at Stryker Corporation, overseeing financial operations, mergers and acquisitions, and regulatory reporting.

These appointments are expected to enhance Telix’s strategic oversight and operational expertise, supporting the company’s continued growth and long-term development in the healthcare and biopharmaceutical sectors.